Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL 3-Year EPS without NRI Growth Rate is 28.60% as of Jun. 2026, which is 0% above its 10-year median of 28.50. The stock has 7 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Control Bionics ranks better than 74.62% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 28.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Control Bionics was 28.60% per year. The lowest was 10.40% per year. And the median was 28.50% per year.
Control Bionics (ASX:CBL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Control Bionics 3-Year EPS without NRI Growth Rate Related Terms
ASX:CBL vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Control Bionics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Control Bionics's 3-Year EPS without NRI Growth Rate falls into.
Control Bionics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 28.60% mean?
Control Bionics (ASX:CBL) has a 3-Year EPS without NRI Growth Rate of 28.60% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Control Bionics and its competitors. This is near median its historical median of 28.50. Over the past decade, Control Bionics' 3-Year EPS without NRI Growth Rate has ranged from 10.40 to 28.60. According to the industry distribution chart, Control Bionics ranks #168 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 25.4%.
Is Control Bionics' 3-Year EPS without NRI Growth Rate too high?
Control Bionics' current 3-Year EPS without NRI Growth Rate of 28.60% is near median its 10-year median of 28.50. Over the past 10 years, this metric has ranged from a low of 10.40 to a high of 28.60. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Control Bionics' value of 28.60% is 255.3% above this industry median. Based on the distribution chart, Control Bionics ranks #168 out of 662 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Control Bionics' 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #168 out of 662 companies for 3-Year EPS without NRI Growth Rate. This puts Control Bionics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Control Bionics' value of 28.60% is 255.3% above this benchmark. Historically, Control Bionics' own 3-Year EPS without NRI Growth Rate has ranged from 10.40 to 28.60 over the past decade. While the company's 10-year median is 28.50 vs. the industry median of 8.05, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current 3-Year EPS without NRI Growth Rate of 28.60% is 255.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current 3-Year EPS without NRI Growth Rate is 28.60%, which is near median its own 10-year median of 28.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.06 — trading 205% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 28.60%, which is near median its 10-year median of 28.50 and 255.3% above the Medical Devices & Instruments industry median of 8.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current 3-Year EPS without NRI Growth Rate is 28.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
